Beactica Announces Drug Discovery Collaboration with Arrow Therapeutics
News Nov 13, 2007
Beactica AB has announced that it has entered into a drug discovery collaboration agreement with Arrow Therapeutics Ltd (London, UK) whereby Beactica will direct its characterization technology at selected Arrow compounds against a confidential target.
"We are very pleased to be working with Arrow" said Beactica's CEO, Dr Per Kallblad. "The company has a world-class reputation for conducting break through research in the antiviral field and we look forward to applying our technology on their targets."
CEO of Arrow Therapeutics, Dr Ken Powell, said "Working with Beactica provides us with an opportunity to apply a new technology that has already shown strong potential."
2nd International Conference on Pharmaceutical Research & Innovations in Pharma Industry
May 30 - May 31, 2019